Image
NASH Diagnostics Forum™

A Critical Appraisal of Non-Invasive Technologies in NASH

Informing the Future of NASH Diagnosis and Assessment

Suggested Readings

Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials.

Anstee QM, Lawitz EJ, Alkhouri N, et al. Hepatology. 2019;70(5):1521-1530.

Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action.

Bril F, Cusi K. Diabetes Care. 2017;40(3):419-430.

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis.

Dulai PS, Singh S, Patel J, et al. Hepatology. 2017;65(5):1557-1565.

Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease.

Eddowes PJ, Sasso M, Allison M, et al. Gastroenterology. 2019;156(6):1717-1730.

Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening.

Lomonaco R, Godinez Leiva E, Bril F, et al. Diabetes Care. 2021;44(2):399-406.

Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States Is cost-effective: a comprehensive cost-utility analysis.

Noureddin M, Jones C, Alkhouri N, et al. Gastroenterology. 2020;159(5):1985-1987.e1984.

Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease.

Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Clin Gastroenterol Hepatol. 2019;17(1):156-163.e152.

Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.

Srivastava A, Gailer R, Tanwar S, et al. J Hepatol. 2019;71(2):371-378.

Update on NAFLD genetics: from new variants to the clinic.

Trépo E, Valenti L. J Hepatol. 2020;72(6):1196-1209.

The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis.

Younossi ZM, Golabi P, de Avila L, et al. J Hepatol. 2019;71(4):793-801.

Performance of the enhanced liver fibrosis test to estimate advanced fibrosis among patients with nonalcoholic fatty liver disease.

Younossi ZM, Felix S, Jeffers T, et al. JAMA Netw Open. 2021;4(9):e2123923.

Role of noninvasive tests in clinical gastroenterology practices to identify patients with nonalcoholic steatohepatitis at high risk of adverse outcomes: expert panel recommendations.

Younossi ZM, Noureddin M, Bernstein D, et al. Am J Gastroenterol. 2021;116(2):254-262.

Relevant Resources

PrEP for Your Patients’ Needs

The PCPs Role in Preventing HIV

Value-Based HIV Formularies

Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Targeting NASH

Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis

Hepatitis C is Curable

Got it? Treat it!

Real-World Issues in HIV Prevention & Treatment

The Critical Role of the Community Pharmacist

BLOCK HIV/HCV

Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

Evolving Models of HIV Care

Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box

The Nexus of NASH and Type 2 Diabetes Mellitus

The Emerging Role of the Diabetologist

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

The Changing Landscape of IBD

Emerging Concepts in Patient Management

The Big (& Small) Picture of Nonalcoholic Steatohepatitis

Building Your Understanding to Combat a Growing Problem

Evolving Models of HIV Care

Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today

HIV as a Chronic Disease

A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities

The Pursuit of Hepatitis C Elimination

How the Pharmacist Can Make a Difference

Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCV

Understanding the Growing Syndemic — Opioids, HCV, and HIV

Trends and Updates in IBD

Appraising the Therapeutic Armamentarium in Moderate and Severe Disease

Stepping Up to the Challenge

The PCP’s Role in HCV Elimination

The Changing Landscape of HIV Prevention

What the Pharmacist Needs to Know about PrEP

Evolving Models of HIV Care (Volume 3)

The Rapid ART Standard of Care: From Evidence to Healthcare Equity

HIV Updates for Pharmacy Practice

Maximizing Your Role to Impact Patient Outcomes

BRIDGE HCV

Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Case Challenges in HIV Medicine

Benefits, Barriers, & Best Practices in an Advancing Field

Challenges and Opportunities in HIV

Practical Solutions Across the Spectrum of Care

Expanding HIV Prevention in Colorado—and Nationwide

A PEP/PrEP Training Guide for Pharmacists

Setting a Course for the Optimal Management of IBD

An Interactive Learning Experience

Optimizing Advanced Therapies in Ulcerative Colitis: Is Your Practice Up to Date?

A Focus on Clinical Evidence and Guideline Recommendations

Treating Hepatitis C in the Primary Care Setting

A Critical Step Toward HCV Elimination

Honing Clinical Skills in HIV Treatment

Considering the Patient, the Provider, and the Science

Hot Topics in HCV

A Multidisciplinary Online Mini-Curriculum

IBD Journal Club:

Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD

Clinical Issues in COVID-19

Debates and Discussions about Monoclonal Antibody Therapies

Minimizing Patient Risks From COVID-19

An Update on Monoclonal Antibody Therapies

Treating Hepatitis C in the Primary Care Setting

Establishing Clinical Readiness Through Mentored Learning

Finding the Path in Eosinophilic Esophagitis

Interdisciplinary Strategies for Adult and Pediatric Patients

Answering the Call

Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema

Putting a Spotlight on Systemic Mastocytosis

A Multidisciplinary Look at Early Diagnosis and Management

Clinical Updates in COVID-19

Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment

Is It Systemic Mastocytosis?

Best Practices for Diagnosis and Management

Monoclonal Antibodies for COVID-19

An Update on Best Practices

Monoclonal Antibodies for COVID-19

New Avenues to Pre-Exposure Prophylaxis

Virologic Failure in HIV

An Updated Clinician’s Guide to Assessment and Management

Applying HIV Advances in Practice

What the Pharmacist Needs to Know

Buffing Up on New and Emerging ART

A Look at the Changing HIV Playing Field

Pharmacy PrEP Education

A “How To” Series Spanning Policy to Practice

BRIDGE PrEP

Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention

Long-Acting Injectable PrEP:

Bringing HIV Prevention to a New Level

PrEParing to End the Epidemic

Optimizing HIV Prevention in Primary Care

A Call to Action

Monoclonal Antibodies for the Prevention and Treatment of COVID-19

What’s Next

Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis

Answers to Everyday Practice Challenges in HIV Medicine

A Phone-a-Friend CME Series – Volume 2

What’s New in the Management of COVID-19

Incorporating New Data and Updated Guidelines Into Daily Practice

Strengthening Your COVID-19 Management Technique

Exercising Best Practices for Hospitalized Patients